KRAS and acute lymphoblastic leukemia: Several studies have showed that mutations in genes that activate the Ras/Raf/Mek/Erk pathway (NRAS, KRAS, FLT3, and PTPN11) are encountered in relapsed ALL and seem to respond to the MEK inhibitor selumetinib (Figure 1).